

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 December 2009 (17.12.2009)(10) International Publication Number
WO 2009/150194 A1

(51) International Patent Classification:

A61K 31/497 (2006.01) A61P 31/14 (2006.01)
A61K 31/7056 (2006.01) A61K 38/21 (2006.01)
A61K 47/48 (2006.01)

(21) International Application Number:

PCT/EP2009/057222

(22) International Filing Date:

10 June 2009 (10.06.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08157986.4 10 June 2008 (10.06.2008) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEUMONT, Maria Gloria** [US/FR]; c/o Janssen-Cilag, 1 rue Camille Desmoulins, F-92787 Issy Les Moulineaux (FR). **HERDINIUS, Stefan, Rikard**; c/o Tibotec-Virco Virology BVBA, Generaal De Wittelaan L 11B 3, 2800 Mechelen (BE). **PICCHIO, Gaston, Rafael**; c/o Tibotec, Inc., 1020 Stony Hill Road, Suite 300, Yardley, PA 19067 (US).

POLO, Ramon; c/o Tibotec, Inc., 1020 Stony Hill Road, Suite 300, Yardley, PA 19067 (US).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm. VA, J&J Patent Law Department, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TELAPREVIR DOSING REGIMEN




Figure 1

(57) Abstract: This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin.



Published:

— *with international search report (Art. 21(3))*